Effects of raloxifene on insulin sensitivity, β-cell function, and hepatic insulin extraction in normal postmenopausal women

Fertility and Sterility

Volumn 89, Issue 3, 2008, Pages 614-619

  Nagamani, Manubai ^a   Szymajda, Alexandria ^a   Sepilian, Vicken ^a   Urban, Randall J ^a   Gilkison, Charles ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

cell function; insulin sensitivity; Raloxifene

Indexed keywords

C PEPTIDE; INSULIN; PROINSULIN; RALOXIFENE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CELL FUNCTION; CLINICAL TRIAL; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; INSULIN BLOOD LEVEL; INSULIN CLEARANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULIN TOLERANCE TEST; NORMAL HUMAN; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; UNITED STATES;

BLOOD GLUCOSE; C-PEPTIDE; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; LIPIDS; LIVER; MIDDLE AGED; POSTMENOPAUSE; PROSPECTIVE STUDIES; RALOXIFENE; REFERENCE VALUES; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TIME FACTORS;

EID: 40249093057     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2007.03.083     Document Type: Article

References (24)

1. Psoudler A.J., Felton C.V., and Stevenson J.C. Aging and the response of plasma insulin, glucose and C-peptide concentrations to intravenous glucose in postmenopausal women. Clin Sci 83 (1992) 489-494
2. Walton C., Godsland I.F., Psoudler A.J., Wynn V., and Stevenson J.C. The effects of the menopause on insulin sensitivity, secretion and elimination in non-obese healthy women. Eur J Clin Invest 23 (1993) 466-473
3. Poehlman E.T., Toth M.J., and Gardner A.W. Changes in energy balance and body composition at menopause: a controlled longitudinal study. Ann Intern Med 123 (1995) 673-675
4. Park Y.W., Zhu S., Palaniappan L., Heshka S., Carnethon M.R., and Heymsfield S.B. The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 163 (2003) 427-436
5. Pyorala K., Savolainen E., Kaukola S., and Haapakoski J. Plasma insulin as coronary heart disease risk factor: relationship to other risk factors and predictive value during 9 1/2 follow-up of Helsinki Policeman Study population. Acta Med Scand 701 (1985) 38-52
6. Laakso M., and Barret-Connor E. Asymptomatic hyperglycemia is associated with lipid and lipoprotein changes favoring atherosclerosis. Arteriosclerosis 9 (1989) 665-672
7. Barret-Connor E.L., Cohen B.A., Wingard D.L., and Edelstein S.L. Why diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernado Study. JAMA 265 (1991) 627-631
8. Cefalu W.T., Wagner J.D., Bell-Farrow A.D., Wang Z.Q., Adams M.R., Toffolo G., et al. The effects of hormonal replacement therapy on insulin sensitivity in surgically menopausal cynomolgus monkeys (Macaca fasicularis). Am J Obstet Gynecol 171 (1994) 440-445
9. Lindheim S.R., Presser S.C., Ditkoff E.C., Vijod M.A., Stanczyk F.Z., and Lobo R.A. A possible bimodal effect of estrogen on insulin sensitivity in postmenopausal women and the attenuating effect of added progestins. Fertil Steril 60 (1993) 664-667
10. Shadoan M.K., Anthony M.S., Rankin S.E., Clarkson T.B., and Wagner J.D. Effects of tibolone and conjugated equine estrogens with or without medroxyprogesterone acetate on body composition and fasting carbohydrate measures in surgically menopausal monkeys. Metabolism 52 (2003) 1085-1091
11. Ettinger B., Black D.M., Mitlak B.H., Knickerbocker R.K., Nickelson T., Genant H.K., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3 year randomized clinical trial. JAMA 282 (1999) 637-645
12. Gresa T.A., Sluka L.P., Bryant H.U., Cullinan G.J., Glarebrook A.L., Jones C.D., et al. Molecular determinants of tissue selectivity in estrogen receptor modulators. Proc Natl Acad Sci USA 94 (1997) 14105-14110
13. Andersson B., Johannsson G., Holm G., Bengtsson B., Sashegyi A., Pavo I., et al. Raloxifene did not affect insulin sensitivity or glycemic control in postmenopausal women with type 2 diabetes mellitus: a randomized clinical trial. J Clin Endocrinol Metab 87 (2002) 122-128
14. Mathews D.R., Hoeker J.P., Rudenski A.S., Nayer B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
15. Rizza R.A., Mandarino L.J., and Gerich J.E. Dose-response characteristics for effects of insulin on production and utilization of glucose in man. Am J Physiol 240 (1981) E630-E639
16. Stuart C.A., and Nagamani M. Insulin infusion acutely augments ovarian androgen production in normal women. Fertil Steril 54 (1990) 788-792
17. Cauley J., Robbins J., Chen Z., Cummings S.R., Jackson R.D., LaCroix A.Z., et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. Women's Health Initiative Investigators. JAMA 290 (2003) 1729-1738
18. Delmas P.D., Ensrud K.E., Adachi J.D., Harper K.D., Sarkar S., Gennari C., et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation Investigators. J Clin Endocrinol Metab 87 (2002) 3609-3617
19. Cucinelli F., Soranna L., Romualdi D., Muzj G., Mancuso S., and Lanzone A. The effect of raloxifene on glycol-insulinemic homeostasis in healthy postmenopausal women: a randomized placebo-controlled study. J Clin Endocrinol Metab 87 (2002) 4186-4192
20. Cagnacci A., Paoletti A.M., Zanni A., Arangino S., Ibba G., Orru M., et al. Raloxifene does not modify insulin sensitivity and glucose metabolism in postmenopausal women. J Clin Endocrinol Metab 87 (2002) 4117-4121
21. Lee C.C., Kasa-Vubu J.Z., and Supiano M.A. Differential effects of raloxifene and estrogen on insulin sensitivity in postmenopausal women. J Am Geriatr Soc 51 (2003) 683-688
22. Oleksik A.M., Duong T., Pliester N., Asma G., Popp-Snijders C., and Lips P. Effects of the selective estrogen receptor modulator, raloxifene, on the somatotropic axis and insulin-glucose homeostasis. J Clin Endocrinol Metab 86 (2001) 2763-2768
23. Faber O.K., Christensen K., Kehlet H., Madsbad S., and Binder C. Decreased insulin removal contributes to hyperinsulinemia in obesity. J Clin Endocrinol Metab 53 (1981) 618-621
24. Cagnacci A., Soldani R., Carriero P.L., Paoletti A.M., Fioretti P., and Melis G.B. Effects of low doses of transdermal 17 beta-estradiol on carbohydrate metabolism in postmenopausal women. J Clin Endocrinol Metabol 74 (1992) 1396-1400